Mediox Inhalatiegas (Oxygen)

Oxygen serves as the final electron acceptor in cellular respiration. When inhaled, it diffuses across the alveolar membrane into the bloodstream, binds to hemoglobin, and raises arterial oxygen tension. This increased oxygen availability enhances delivery to tissues, supporting aerobic metabolism and ATP production, which is essential for normal cellular function.

The prescribed dose of Mediox Inhalatiegas is determined by the treating clinician based on the patient’s oxygen saturation, underlying condition, and clinical setting. The prescriber selects the appropriate flow rate, concentration, and duration to achieve target oxygen levels, and these parameters are individualized for each patient.

Data on the use of supplemental oxygen in pregnancy and lactation are limited. Oxygen therapy is generally considered safe when clinically indicated, but the benefits must outweigh any potential risks. Healthcare providers should evaluate each case individually and monitor both mother and fetus or infant closely.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including any cold‑chain requirements), and required import documentation.

Mediox Inhalatiegas provides medical‑grade oxygen in bulk cylinders or portable canisters, meeting EU standards for purity. Compared with ambient air or low‑flow nasal cannula systems, it delivers a higher and more controlled concentration of oxygen, which is essential for severe hypoxemia or surgical settings. It is comparable to other pharmaceutical oxygen products but offers flexible packaging for diverse clinical needs.

The product should be stored at ambient temperature in a well‑ventilated, dry area away from direct sunlight and heat sources. Cylinders must be secured upright to prevent tipping, and valves should be kept closed when not in use. Keep away from open flames, sparks, and smoking materials to reduce fire risk.

Mediox Inhalatiegas is administered via inhalation using appropriate delivery devices such as nasal cannulas, simple face masks, or non‑rebreather masks. The prescriber sets the flow rate and oxygen concentration based on the patient’s needs. Proper fitting of the device ensures efficient delivery and minimizes waste.

The most serious risks include fire hazards due to the high flammability of enriched oxygen environments, pulmonary oxygen toxicity from prolonged exposure to high concentrations, and central nervous system toxicity at very high pressures, which can manifest as seizures or visual disturbances. Continuous monitoring mitigates these risks.

Patients with known hypersensitivity to oxygen therapy components, those with untreated severe chronic lung disease where high‑flow oxygen may worsen hypercapnia, and individuals in environments where fire risk cannot be controlled should avoid its use. Neonates and premature infants require specialized oxygen delivery and monitoring.